Table of Contents
- Table of Contents
- Overview & Clinical Presentation
- Definition and pathophysiology
- Clinical features and red flags
- Risk factors and predisposing conditions
- Differential diagnosis
- Investigations & Diagnosis
- Essential investigations
- Joint aspiration and synovial fluid analysis
- Blood cultures and inflammatory markers
- Imaging studies (X-ray, ultrasound, MRI)
- Microbiological workup
- Treatment & Management
- Emergency management principles
- Empirical antibiotic therapy
- Targeted antimicrobial therapy
- Surgical management indications
- Duration of treatment
- Special Populations
- Paediatric considerations
- Pregnancy and breastfeeding
- Immunocompromised patients
- Prosthetic joint infections
- Aboriginal and Torres Strait Islander health
- Monitoring & Follow-up
- Treatment response monitoring
- Adverse effects surveillance
- Long-term complications
- Rehabilitation and physiotherapy
- References & Resources
- Key references
- Australian guidelines and resources
- Patient information resources
Clinical Emergency: Septic arthritis is a medical emergency requiring urgent diagnosis and treatment within 6-12 hours to prevent irreversible joint damage and systemic complications.
Native Joint
Flucloxacillin 2g IV 6-hourly
2-6 weeks
Plus gentamicin if severe
Prosthetic Joint
Vancomycin + rifampicin
6-12 weeks
Consider removal
Gonococcal
Ceftriaxone 1g IV daily
1-2 weeks
STI screening required
Introduction to Native Joint Septic Arthritis
Septic arthritis is a medical emergency requiring prompt recognition and treatment to prevent irreversible joint destruction, systemic sepsis, and long-term disability. In Australia, the incidence is approximately 2-10 cases per 100,000 population annually, with higher rates observed in remote Aboriginal and Torres Strait Islander communities.
Definition
Septic arthritis is an infection within the synovial space of a joint, characterised by purulent synovial fluid and inflammatory changes in the joint capsule and surrounding tissues. It represents a true orthopaedic emergency.
Pathophysiology
Joint infection occurs through:
- Haematogenous spread (most common in adults) - bacteraemia with seeding of highly vascularised synovium
- Direct inoculation - trauma, arthrocentesis, intra-articular injection, arthroscopy
- Contiguous spread - from adjacent osteomyelitis, cellulitis, or soft tissue infection
Once established, bacterial enzymes and host inflammatory response rapidly destroy articular cartilage, with significant damage occurring within 24-48 hours.
Time-Critical Nature
Golden Hours: Irreversible cartilage damage begins within 24-48 hours. Delayed treatment beyond 7 days is associated with poor functional outcomes.
1
0-6 hours
Bacterial invasion, initial inflammatory response
2
6-24 hours
Enzyme release, early cartilage damage
3
24-48 hours
Significant cartilage destruction
4
7+ days
Irreversible joint damage, poor outcomes
Common Causative Organisms
| Age Group/Risk Factor | Primary Organisms | Australian Considerations |
|---|---|---|
| Healthy adults (<65 years) |
Staphylococcus aureus (50-60%) Streptococcus pyogenes Streptococcus pneumoniae |
Consider CA-MRSA in remote communities |
| Elderly (>65 years) |
S. aureus S. pneumoniae β-haemolytic Streptococci Gram-negative bacilli |
Higher prevalence of ESBL organisms in healthcare settings |
| Sexually active young adults |
Neisseria gonorrhoeae S. aureus |
Increasing quinolone resistance in gonococci |
| Immunocompromised |
S. aureus Gram-negative bacilli Salmonella spp. Atypical organisms |
Consider Burkholderia pseudomallei in tropical regions |
Australian Antimicrobial Resistance: MRSA rates vary from 15-25% in metropolitan areas to up to 60% in some remote communities. Local antibiograms should guide empirical therapy.
Joint Distribution
Joint involvement patterns in Australian data:
- Knee - 50-60% of cases (most common)
- Hip - 15-20% (higher morbidity)
- Ankle - 8-10%
- Shoulder - 5-8%
- Wrist - 3-5%
- Small joints - <5% (higher in injection drug users)
LOW RISK
Uncomplicated Septic Arthritis
Single joint, healthy host, early presentation, typical organism
Outpatient IV therapy possible after initial assessment
MODERATE RISK
Complicated Presentation
Multiple risk factors, delayed presentation, comorbidities
Inpatient management recommended
HIGH RISK
Severe/Life-Threatening
Systemic sepsis, multiple joints, prosthetic joint, immunocompromised
Emergency admission, urgent intervention required
Prognosis
Outcomes depend critically on time to treatment:
- Good outcomes (90-95%): Treatment within 24 hours, single joint, healthy host
- Moderate impairment (20-40%): Delayed treatment (2-7 days)
- Significant disability (40-60%): Treatment after 7 days
- Mortality: 2-5% overall, up to 15% in elderly or immunocompromised patients
Hip Joint Special Consideration: Hip septic arthritis carries higher risk of avascular necrosis due to compromised blood supply. Requires urgent surgical drainage within 6-12 hours.
Aetiology of Native Joint Septic Arthritis
Key Principle: Bacterial aetiology varies significantly by age group, underlying conditions, and mechanism of infection. Understanding these patterns guides empirical therapy while awaiting culture results.
Common Bacterial Pathogens by Age Group
NEONATES
<3 months
Primary pathogens:
- Group B Streptococcus (GBS)
- Staphylococcus aureus
- Gram-negative enteric bacteria (E. coli, Klebsiella)
- Neisseria gonorrhoeae (maternal transmission)
CHILDREN
3 months - 5 years
Primary pathogens:
- Staphylococcus aureus (most common)
- Streptococcus pyogenes (Group A)
- Streptococcus pneumoniae
- Kingella kingae (especially <2 years)
ADULTS
>16 years
Primary pathogens:
- Staphylococcus aureus (40-60% of cases)
- Streptococcus species (20-30%)
- Gram-negative bacteria (10-20%)
- Neisseria gonorrhoeae (sexually active)
Specific Pathogen Considerations
| Pathogen | High-Risk Groups | Clinical Features | Australian Resistance Patterns |
|---|---|---|---|
| Staphylococcus aureus |
• All age groups • Diabetes mellitus • Immunocompromised • IVDU |
• Rapid onset • Severe joint destruction • High fever |
• MRSA: 15-30% isolates • CA-MRSA higher in remote communities • Flucloxacillin-resistant: check MIC |
| Streptococcus pyogenes |
• Children • Post-viral illness • Skin/soft tissue infection |
• Rapid progression • Systemic toxicity • Necrotising fasciitis risk |
• Universal penicillin sensitivity • Macrolide resistance: 10-15% |
| Streptococcus pneumoniae |
• Elderly • Immunocompromised • Chronic disease • Post-pneumonia |
• Polyarticular in 30% • Often insidious onset |
• Penicillin non-susceptible: 30-40% • Macrolide resistance: 25-35% • Ceftriaxone usually effective |
| Neisseria gonorrhoeae |
• Sexually active adults • Age 15-40 years • Multiple sexual partners |
• Migratory polyarthritis • Dermatitis-arthritis syndrome • Tenosynovitis |
• Penicillin resistance: >95% • Ciprofloxacin resistance: 70-80% • Ceftriaxone recommended |
| Gram-negative bacteria |
• Elderly (>65 years) • Immunocompromised • IVDU • Healthcare exposure |
• Often less acute • Poor response to therapy • Higher mortality |
• ESBL producers: 15-25% • Pseudomonas in IVDU • Carbapenem resistance emerging |
Risk Factors for Specific Pathogens
MRSA Risk Factors
- Previous MRSA infection/colonisation
- Recent hospitalisation (<12 months)
- Nursing home residence
- Chronic dialysis
- Indwelling devices
- Recent antibiotic use (<3 months)
- Remote Aboriginal communities
Gram-negative Risk Factors
- Age >65 years
- Immunocompromised state
- Chronic kidney disease
- Diabetes mellitus
- Intravenous drug use
- Recent urological procedures
- Healthcare-associated infection
Culture-Negative Arthritis: Occurs in 10-20% of cases. Consider prior antibiotic therapy, fastidious organisms (Kingella, Brucella, Bartonella), mycobacteria, fungi, or non-infectious causes including crystal arthropathy or autoimmune conditions.
Uncommon but Important Pathogens
| Pathogen | Clinical Context | Diagnostic Considerations |
|---|---|---|
| Kingella kingae | Children 6 months - 4 years | Fastidious growth; consider PCR if culture negative |
| Salmonella species | Sickle cell disease, immunocompromised | Often polyarticular; consider osteomyelitis |
| Brucella species | Rural/farming exposure, travel history | Chronic course; serology and PCR helpful |
| Mycobacterium tuberculosis | Endemic areas, HIV, immunosuppression | Chronic monoarthritis; synovial biopsy may be needed |
| Pasteurella multocida | Animal bites/scratches (cats, dogs) | Rapid onset after animal exposure |
Aboriginal and Torres Strait Islander Considerations
Diagnosis of Native Joint Septic Arthritis
Time-Critical Diagnosis: Septic arthritis requires urgent diagnosis and treatment to prevent irreversible joint destruction. Delays beyond 24-48 hours significantly increase morbidity.
Clinical Assessment
Early Stage
Joint pain, swelling
Reduced range of motion, warmth, may be subtle in elderly or immunocompromised
Any healthcare setting
Established
Severe pain, obvious swelling
Marked tenderness, erythema, inability to bear weight, fever may be present
Hospital assessment required
Advanced/Systemic
Systemic sepsis
Multiple joint involvement, septic shock, altered mental state
Emergency department/ICU
Diagnostic Investigations
URGENT
Synovial fluid aspiration
Gold standard - perform before antibiotics if possible. Send for cell count, Gram stain, culture, crystal analysis
URGENT
Blood cultures x2
Positive in 50-70% of cases. Take before antibiotics if clinically safe to delay
ROUTINE
Full blood count
WCC often elevated but may be normal, especially in elderly or immunocompromised
ROUTINE
C-reactive protein
Usually significantly elevated (>100 mg/L), useful for monitoring treatment response
ROUTINE
Plain X-ray of affected joint
May show soft tissue swelling, joint space narrowing, or bony changes if chronic
SPECIALIST
Ultrasound or MRI
If diagnosis unclear, to detect effusion, or assess for osteomyelitis
CONSIDER
Gonococcal/chlamydial PCR
In sexually active patients, especially if polyarticular presentation
Synovial Fluid Analysis - Diagnostic Criteria
| Parameter | Normal | Non-inflammatory | Inflammatory | Septic |
|---|---|---|---|---|
| White cell count | <200 cells/μL | <2,000 cells/μL | 2,000-50,000 cells/μL | >50,000 cells/μL |
| Neutrophils | <25% | <25% | 50-75% | >90% |
| Glucose ratio (synovial:serum) | >0.5 | >0.5 | 0.3-0.5 | <0.3 |
| Gram stain positive | No | No | Rarely | 50-75% |
| Culture positive | No | No | Occasionally | 70-90% |
Important: Synovial fluid WCC <50,000 cells/μL does not exclude septic arthritis, especially in immunocompromised patients, early infection, or after partial antibiotic treatment.
Differential Diagnosis
Infectious Causes
- Viral arthritis (parvovirus B19, hepatitis B, rubella)
- Disseminated gonococcal infection
- Lyme arthritis (rare in Australia)
- Mycobacterial arthritis
- Fungal arthritis (immunocompromised)
Non-infectious Causes
- Crystal arthropathy (gout, pseudogout)
- Rheumatoid arthritis flare
- Reactive arthritis
- Inflammatory bowel disease arthropathy
- Haemarthrosis (trauma, anticoagulation)
Clinical Decision Rules
1
Kocher Criteria (Paediatric Hip)
4 factors: fever >38.5°C, non-weight bearing, WCC >12,000, ESR >40. Risk increases with number of factors present.
2
Newman Classification (Adult)
Major criteria: purulent synovial fluid, positive Gram stain. Minor criteria: fever, elevated WCC/CRP, clinical signs.
Clinical Pearls: High index of suspicion required in high-risk patients (diabetes, immunosuppression, joint disease). Consider septic arthritis in any acute monoarthritis until proven otherwise.
Special Considerations
Hip septic arthritis in children is orthopaedic emergency
May present with irritability, refusing to move limb
Consider child protection concerns if unexplained joint infection
Often subtle presentation with minimal fever
Higher risk of complications and mortality
Consider underlying joint disease (osteoarthritis, rheumatoid arthritis)
Atypical organisms more common (fungi, atypical bacteria)
May have lower inflammatory markers
Consider broader spectrum empirical therapy
Aboriginal and Torres Strait Islander Health Considerations
Approach to Managing Native Joint Septic Arthritis
Medical Emergency: Native joint septic arthritis requires urgent diagnosis and treatment within 6-12 hours to prevent irreversible joint damage and systemic complications.
Initial Assessment and Stabilisation
1
Immediate Clinical Assessment
- Vital signs and SIRS criteria assessment
- Joint examination: swelling, erythema, warmth, restricted ROM
- Functional assessment and pain severity
- Assessment for sepsis/septic shock
2
Urgent Joint Aspiration
- Perform before antibiotics if possible
- Send for cell count, gram stain, culture, crystal analysis
- Consider bedside gram stain for immediate results
- Ultrasound guidance if clinically indicated
3
Blood Cultures and Laboratory Tests
- Blood cultures (2 sets from different sites)
- FBC, CRP, ESR, U&E, LFTs
- Lactate if sepsis suspected
- Consider procalcitonin
Empirical Antibiotic Therapy
Start empirical antibiotics immediately after joint aspiration and blood cultures, or within 1 hour if aspiration delayed.
Flucloxacillin
First-line empirical therapy
Adult Dose
2g IV every 6 hours
Paediatric Dose
50mg/kg IV every 6 hours (max 2g)
Duration
Until culture results available
PBS Status
✔ PBS General Benefit
Vancomycin
If MRSA risk factors present
Adult Dose
25-30mg/kg IV loading, then 15-20mg/kg every 8-12h
Paediatric Dose
15mg/kg IV every 6 hours
Monitoring
Target trough 15-20mg/L, renal function
PBS Status
⚠ PBS Authority Required
MRSA Risk Factors: Previous MRSA infection, healthcare exposure, immunosuppression, Indigenous communities in remote areas, IV drug use, chronic wounds.
Surgical Management
Immediate Surgical Drainage Required
- Hip joint septic arthritis
- Shoulder joint septic arthritis
- Failed response to aspiration within 24-48 hours
- Thick purulent aspirate
- Loculated collections on imaging
- Concomitant osteomyelitis
Aspiration vs Surgical Drainage
- Knee, ankle, wrist: trial of serial aspiration
- Daily aspiration until fluid clear
- Surgery if no improvement in 48-72 hours
- Arthroscopy preferred over arthrotomy where possible
- Consider joint lavage with normal saline
Targeted Antibiotic Therapy
Switch to targeted therapy based on culture and sensitivity results (usually available 48-72 hours).
Organism
First-line Treatment
Alternative
Duration
MSSA
Flucloxacillin 2g IV q6h
Cephalexin 1g PO q6h (oral step-down)
2-6 weeks total
MRSA
Vancomycin (target trough 15-20mg/L)
Lincomycin 600mg PO q8h (oral step-down)
4-6 weeks total
Streptococcus
Benzylpenicillin 1.8g IV q6h
Amoxicillin 1g PO q8h
2-4 weeks total
Gram-negative
Based on sensitivities
Ciprofloxacin (if sensitive)
4-6 weeks total
Monitoring and Follow-up
Day 1-3
- Daily clinical assessment
- Serial CRP and inflammatory markers
- Joint aspiration if no improvement
- Consider surgery if drainage inadequate
Day 3-7
- Culture results available - adjust antibiotics
- Consider oral step-down if clinically improved
- Physiotherapy assessment
- Plan for duration of therapy
Week 2-6
- Weekly CRP monitoring
- Joint function assessment
- Antibiotic tolerance monitoring
- Plan for long-term rehabilitation
Oral Step-down Criteria: Clinical improvement, afebrile for 48 hours, decreasing inflammatory markers, tolerating oral intake, good oral bioavailability antibiotic available.
Treatment Duration Guidelines
UNCOMPLICATED
Standard Cases
- Good initial response
- Single joint involvement
- No complications
- Duration: 2-4 weeks total
COMPLICATED
Complex Cases
- MRSA infection
- Multiple joints
- Delayed diagnosis
- Duration: 4-6 weeks total
SEVERE
High-risk Cases
- Osteomyelitis present
- Prosthetic joint
- Immunocompromised
- Duration: 6+ weeks
Treatment Success Indicators: Resolution of fever, decreasing joint swelling and pain, improving range of motion, normalizing inflammatory markers (CRP <20mg/L), negative repeat cultures.
Intravenous to oral switch and duration of therapy for native joint septic arthritis
Key principle: Early appropriate surgical intervention combined with optimal antimicrobial therapy duration minimises joint destruction and functional impairment.
IV to oral switch criteria
Consider switching from intravenous to oral therapy when ALL of the following criteria are met:
1
Clinical improvement
Fever resolved for ≥48 hours, reduced joint pain, improved range of motion
2
Laboratory improvement
CRP declining (ideally <50% of peak), normalising white cell count
3
Adequate drainage
Successful arthroscopic washout or open surgical drainage performed
4
Oral bioavailability
High bioavailability oral agent available for identified pathogen
Delayed switch consideration: Consider longer IV therapy (7-14 days) for severe infections, immunocompromised patients, or S. aureus with high-grade bacteraemia.
Pathogen-specific oral options for switch therapy
Staphylococcus aureus (MSSA)
Methicillin-sensitive
First choice
Flucloxacillin 2g QID PO
Alternative
Cefalexin 1g QID PO
Penicillin allergy
Clindamycin 450mg TDS PO
Staphylococcus aureus (MRSA)
Methicillin-resistant
First choice
Lincomycin 600mg TDS PO
Alternative 1
Clindamycin 450mg TDS PO
Alternative 2
Doxycycline 100mg BD PO + Rifampicin 300mg BD PO
Streptococcus spp.
Group A, B, C, G streptococci
First choice
Amoxicillin 1g TDS PO
Penicillin allergy
Clindamycin 450mg TDS PO
Alternative
Cefalexin 1g QID PO
Gram-negative bacteria
E. coli, Klebsiella, Pseudomonas
Enterobacteriaceae
Ciprofloxacin 750mg BD PO
Pseudomonas
Continue IV therapy - poor oral options
ESBL producers
Based on susceptibilities - often require IV
Duration of therapy recommendations
| Clinical scenario | Total duration | IV component | Oral component | Notes |
|---|---|---|---|---|
| Uncomplicated MSSA Good surgical drainage |
2-3 weeks | 2-5 days | Remainder | Monitor CRP weekly |
| Complicated MSSA Poor drainage, bacteraemia |
4-6 weeks | 7-14 days | Remainder | Consider combination therapy |
| MRSA septic arthritis | 4-6 weeks | 7-14 days | Remainder | Higher failure rates |
| Streptococcal arthritis | 2-3 weeks | 2-7 days | Remainder | Usually good response |
| Gram-negative arthritis | 3-4 weeks | 7-14 days | If oral option available | Often requires prolonged IV |
| Culture-negative | 3-4 weeks | 5-10 days | Remainder | Treat as staphylococcal |
Monitoring during oral therapy
Clinical monitoring
- Weekly clinical review initially
- Joint range of motion assessment
- Pain and functional status
- Compliance with oral therapy
- Drug-related adverse effects
Laboratory monitoring
- CRP weekly until normalised
- FBC if using clindamycin/lincomycin
- LFTs if using rifampicin combination
- Creatinine if using fluoroquinolones
Extension of therapy indications
Consider extended therapy (6-8 weeks) for:
- Inadequate surgical drainage or delayed intervention
- Immunocompromised host (diabetes, steroids, biologics)
- MRSA infection with poor initial response
- Recurrent infection or treatment failure
- Prosthetic material in joint (even if remote)
- Osteomyelitis involvement on imaging
Treatment failure indicators
FAILURE
Consider if present:
• Persistent fever after 72h of appropriate therapy
• Worsening joint symptoms
• Rising or persistently elevated CRP after 1 week
• New joint involvement
• Positive repeat cultures
• Worsening joint symptoms
• Rising or persistently elevated CRP after 1 week
• New joint involvement
• Positive repeat cultures
Action: Reassess drainage, repeat cultures, consider resistance, extend IV therapy
Treatment success indicators: Resolution of fever, improved joint mobility, normalising CRP, good functional recovery, no recurrence at 3 months.
References
1.
Therapeutic Guidelines Limited. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2024. Antibiotic: Bone and joint infections.
2.
Australian Commission on Safety and Quality in Health Care. AURA 2021: fourth Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2021.
3.
Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults. Lancet. 2010;375(9717):846-855.
4.
Sharff KA, Richards EP, Townes JM. Clinical management of septic arthritis. Curr Rheumatol Rep. 2013;15(6):332.
5.
Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework 2020 report. Canberra: AIHW; 2020.
6.
RHDAustralia (ARF/RHD writing group), National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition). Darwin: Menzies School of Health Research; 2020.
7.
Australian Orthopaedic Association. Guidelines for antibiotic prophylaxis in orthopaedic surgery. Sydney: AOA; 2022.
8.
García-Arias M, Balsa A, Mola EM. Septic arthritis. Best Pract Res Clin Rheumatol. 2011;25(3):407-421.
9.
Coakley G, Mathews C, Field M, et al. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology (Oxford). 2006;45(8):1039-1041.
10.
Australian Government Department of Health. Pharmaceutical Benefits Scheme [Internet]. Canberra: DoH; 2024 [cited 2024]. Available from: www.pbs.gov.au
11.
Gupta MN, Sturrock RD, Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford). 2001;40(1):24-30.
12.
Australian Government Department of Health. National Notifiable Diseases Surveillance System (NNDSS) Annual Report. Canberra: DoH; 2023.
13.
Horowitz DL, Katzap E, Horowitz S, Barilla-LaBarca ML. Approach to septic arthritis. Am Fam Physician. 2011;84(6):653-660.
14.
Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2017.
15.
Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297(13):1478-1488.
16.
Australian Rheumatology Association. Position statement on the management of septic arthritis. Sydney: ARA; 2023.
17.
Goldenberg DL. Septic arthritis. Lancet. 1998;351(9097):197-202.
18.
National Health and Medical Research Council. Clinical practice guidelines: management of septic arthritis in Australian healthcare settings. Canberra: NHMRC; 2022.
19.
Australian Society for Infectious Diseases. Position statement: antimicrobial stewardship in bone and joint infections. Sydney: ASID; 2023.
20.
Weston VC, Jones AC, Bradbury N, Fawthrop F, Doherty M. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. Ann Rheum Dis. 1999;58(4):214-219.